COAG· Health Care› Biotechnology

Hemab Therapeutics Holdings, Inc.

$34.82

-1.47% today

$1.6B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is COAG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-05-01 → 2026-10-22

S? 25w

2026-05-012026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 25w current

Total tracked: 25 weeks across 1 stage run.

COAG among Biotechnology587th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…587	COAGHemab Therapeutics Holdings, Inc.	—	—	−5.2%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 25

1w13w26w

Week 25, proven structure

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.81x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-5.2%

-26.4%

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 25 · Vol 0.81x

2026-10-21S—

Wk 24 · Vol 0.75x

2026-10-20S—

Wk 24 · Vol 0.88x

2026-10-19S—

Wk 24 · Vol 0.56x

2026-10-16S—

Wk 24 · Vol 0.77x

2026-10-15S—

Wk 24 · Vol 1.06x

2026-10-14S—

Wk 23 · Vol 0.49x

2026-10-13S—

Wk 23 · Vol 0.95x

2026-10-12S—

Wk 23 · Vol 0.50x

2026-10-09S—

Wk 23 · Vol 1.31x

2026-10-08S—

Wk 23 · Vol 1.31x

2026-10-07S—

Wk 22 · Vol 0.80x

Moving averages & range

50 DMA

$39.62

200 DMA

—

52W High

—

52W Low

—

5D Low

$30.07

Resistance levels (recent highs)

20d High

$35.34

60d High

$54.94

120d High

$54.94

250d High

—

Next resistance

+1.5%

to 20d High

Dividend Yield

0.00%

P/B 3.6

Hemab Therapeutics Holdings: quick answers

Which sector and industry is Hemab Therapeutics Holdings in?

Hemab Therapeutics Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.